Dx
Diagnostic Radiopharmaceutical
Tx
Therapeutic Radiopharmaceutical
rh
Radiohybride
IE
Isotopic Exchange Reaction
OCD
On-Cartidge Drying of F-18
MS
Metabolically Stable or Stabilized Ligand
18F
Flourine-18
68Ga
Galium-68
177Lu
Lutetium-177
225Ac
Actinium-225
CANDIDATE SERIES
siPSMA
- Indication Prostate Cancer and mCRPC
- Application Imaging
- Isotope F-18 prefferably
Preclinical
Transition
Phase 1
Phase 2
Phase 3
Dx
Diagnostic Radiopharmaceutical
Tx
Therapeutic Radiopharmaceutical
rh
Radiohybride
IE
Isotopic Exchange Reaction
OCD
On-Cartidge Drying of F-18
MS
Metabolically Stable or Stabilized Ligand
18F
Flourine-18
68Ga
Galium-68
177Lu
Lutetium-177
225Ac
Actinium-225
CANDIDATE SERIES
sioPSMA
- Indication Prostate Cancer and mCRPC
- Application Therapy
- Isotopes Lu-177, Ac-225
Preclinical
Transition
Phase 1
Phase 2
Phase 3
Dx
Diagnostic Radiopharmaceutical
Tx
Therapeutic Radiopharmaceutical
rh
Radiohybride
IE
Isotopic Exchange Reaction
OCD
On-Cartidge Drying of F-18
MS
Metabolically Stable or Stabilized Ligand
18F
Flourine-18
68Ga
Galium-68
177Lu
Lutetium-177
225Ac
Actinium-225
CANDIDATE SERIES
rhTATE
- Indication Neuroendocrine Tumors
- Application Imaging
- Isotope F-18 preffarably, Ga-68 alternatively
Preclinical
Transition
Phase 1
Phase 2
Phase 3
Dx
Diagnostic Radiopharmaceutical
Tx
Therapeutic Radiopharmaceutical
rh
Radiohybride
IE
Isotopic Exchange Reaction
OCD
On-Cartidge Drying of F-18
MS
Metabolically Stable or Stabilized Ligand
18F
Flourine-18
68Ga
Galium-68
177Lu
Lutetium-177
225Ac
Actinium-225
CANDIDATE SERIES
rhCCK
- Indication Small Cell Lung Cancer (SCLC) & Medullary Thyroid Cancer (MTC)
- Application Therapy & Imaging
- Isotope Lu-177, Ac-225 and F-18
Preclinical
Transition
Phase 1
Phase 2
Phase 3
Dx
Diagnostic Radiopharmaceutical
Tx
Therapeutic Radiopharmaceutical
rh
Radiohybride
IE
Isotopic Exchange Reaction
OCD
On-Cartidge Drying of F-18
MS
Metabolically Stable or Stabilized Ligand
18F
Flourine-18
68Ga
Galium-68
177Lu
Lutetium-177
225Ac
Actinium-225
CANDIDATE SERIES
rhPSMA
- Indication Prostate Cancer and mCRPC
- Application Imaging
- Isotope F-18
Preclinical
Transition
Phase 1
Phase 2
Phase 3
Dx
Diagnostic Radiopharmaceutical
Tx
Therapeutic Radiopharmaceutical
rh
Radiohybride
IE
Isotopic Exchange Reaction
OCD
On-Cartidge Drying of F-18
MS
Metabolically Stable or Stabilized Ligand
18F
Flourine-18
68Ga
Galium-68
177Lu
Lutetium-177
225Ac
Actinium-225
CANDIDATE SERIES
rhPSMA
- Indication Prostate Cancer and mCRPC
- Application Therapy
- Isotope Lu-177, Ac-225
Preclinical
Transition
Phase 1
Phase 2
Phase 3
Dx
Diagnostic Radiopharmaceutical
Tx
Therapeutic Radiopharmaceutical
rh
Radiohybride
IE
Isotopic Exchange Reaction
OCD
On-Cartidge Drying of F-18
MS
Metabolically Stable or Stabilized Ligand
18F
Flourine-18
68Ga
Galium-68
177Lu
Lutetium-177
225Ac
Actinium-225
CANDIDATE SERIES
PSMA PNT 2001
- Indication Prostate Cancer and mCRPC
- Application Therapy
- Isotope Lu-177, Ac-225
Preclinical
Transition
Phase 1
Phase 2
Phase 3